The biopharma world is here. Get the industry’s most comprehensive daily news reports at https://nitter.cf/t.co/qpcDlbaOSx
Global
Joined August 2015
- Tweets51K
- Following80
- Followers32.8K
- Likes4.5K
In this week's Peer Review: Former Be Bio CEO Joanne Smith-Farrell heads to Orbis Medicines, and Enanta's longtime chief Jay Luly is retiring. endpoints.news/after-be-bio-…
Q&A: Anthropic's drug R&D chief Nathan Frey on unmasking "Professor Oak," its preclinical pipeline and critics of its "age of miracles" pitch. endpoints.news/anthropics-na…
AstraZeneca says its reorg could mean R&D cuts and clinical trials shifted to emerging markets. endpoints.news/astrazeneca-s…
The Global Pharma and Biotech Summit, presented by @ftlive in collaboration with Endpoints News, brings together CEOs, regulators and investors to tackle the race to beat the patent cliff, pricing pressure spreading across the Atlantic and the regulatory shifts rewriting launch plans. Register to join us Nov. 10-11 in London and online: event-registration.ft.com/re…
Actio Biosciences spun out the rest of its genetics-driven rare disease pipeline into Setara, which raised $90M. endpoints.news/setara-gets-9…
Is biotech’s future full of zero-employee startups? nitter.cf/i/broadcasts/1jxXgBWyp…
🎙️ Live at 10:30 am ET: Is biotech’s future full of zero-employee startups? @ArmstrongDrew and @AndrewE_Dunn discuss with Dimension’s Simon Barnett. endpoints.news/post-hoc-live…
Battered by late-stage trial failures, AstraZeneca is following GSK with a push to save $1.5B a year. endpoints.news/astrazeneca-f…
Endpoints News retweeted
We'd been talking about this idea since a cool dinner earlier this month at Endpoints' AI day in NYC. After the news that Anthropic had bought @Prof_Oak_ 's one-man-startup Mithril, we pulled the lever for a pop-up show. Gonna be weird, gonna be fun!
youtube.com/live/xZQ8Bn27V1s
Endpoints News retweeted
🦾 Is biotech soon going to be full of zero- and one-employee biotech startups?
Join me, @AndrewE_Dunn + Dimension's @SimonDBarnett about what the weird future might look like.
Today 10:30am ET on @endpts Post-Hoc Live!
endpoints.news/post-hoc-live…
Endpoints News retweeted
Who should we have on Post-Hoc Live tomorrow to talk about zero-employee biotech startups?
Genmab shares jumped about 28% on Phase 3 head and neck cancer data, while Iovance and Coherus tumbled on their own readouts. endpoints.news/genmabs-stock…
Anthropic gave its most detailed look yet at its biopharma ambitions, including bringing its own drugs to the brink of human testing. endpoints.news/anthropic-pit…
Flagship Pioneering is combining three of its portfolio companies into Etcelera to compete in the AI drug discovery field. endpoints.news/flagship-pion…
Lilly beat Wall Street’s revenue estimates by about $2B and raised its full-year outlook for the third straight quarter. Read the full article: endpoints.news/lilly-again-f…
Exclusive: Dren Bio raised $350M to get its lead blood cancer drug onto the market by the end of 2027. endpoints.news/dren-bio-rais…
The landmark daraxonrasib approval in August marked a huge step forward in treatment of pancreatic cancer. But it also opened up gaps in access for some patients waiting for treatment. Tomorrow during the Endpoints at ESMO event, Russ Reed, a pancreatic cancer patient, and his wife and advocate Marnie will share their experiences with those gaps. Join us for that and other key conversations on this moment in oncology: events.endpoints.news/esmo20…
Analysts pressed Biogen on lupus drug litifilimab ahead of Phase 3 readouts pivotal to CEO Chris Viehbacher’s turnaround. endpoints.news/analysts-pres…
⚡️Breaking: HHS says compounders can now make six peptides. endpoints.news/citing-safety…
Scientists have come around on AI: 78% now expect it to speed drug discovery in the next year, up from 59%, per Endpoints’ Signal survey. endpoints.news/now-78-of-sci…
